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Introduction 
 
The liver is labelled as the biggest glandular organ that controls diverse physiological and 
chemical processes in human body. In other words, it plays a central role in metabolic control 
and detoxification involving metabolism of lipids, carbohydrates, alcohol and a wide range of 
drugs as well as toxins (Aseervatham et al., 2018). The liver also participates in innate immune 
function (Gao et al., 2008).Interestingly, the liver has the unique ability to regenerate and 
completely recoup from most acute, non-iterative situation (Mosedale and Watkins, 
2017;Oliva-Vilarnau et al., 2018). However, multiple conditions, e.g., hepatitis, chronic 
alcohol consumption, frequent use of antibiotics associated medications and also even non- 
alcoholic fatty liver disease can affect the regenerative efficacy of the hepatocytes, which 
become totally dysfunctional(Forbes and Newsome, 2016), generally witnessed by the visible 
hepatic scaring, apoptosis and entering into most severe cirrhosis. The liver, when witnesses 
such atrocities, ultimately loses its vitality and thus imbalances the normal metabolic 
phenomenon leading to many other fatal conditions (Branco et al., 2016;DeFronzo et al., 2016). 
Despite considerable amounts of research have been carried out aiming at curing various 
hepatic ailments across the world, limitation still does exist in finding more effective 
hepatoprotective drugs than the currently available medications. Moreover, fewer medications 
promise in restoration effect.  
The Mediterranean-style diet which covers the immense geographical area adjoining the 
Mediterranean Sea focuses the use of root legumes, vegetable, fruits, nuts and seeds 
predominantly (Tuck and Hayball, 2002).  Presently there is an arising concern rather interest 
in exploring the positive effects of plant-based diet for mitigating various chronic diseases 
including several hepatic ailments like hepatic cirrhosis, hepatic ulcerative syndrome and 
fibrosis. It is noteworthy that Mediterranean diet has been allied with many health benefits, is 
characterized by a high intake of fruits, vegetables and nuts containing several bioactive natural 
products of plants. One of such dietary component common in plant-based diets are natural 
phenolics, which are particularly plentiful not only in fruits, whole grains, vegetables and 
legumes but equally in coffee, tea, cocoa and also in red wine. 
Phenolics are a bulky and heterogeneous group of phytochemicals containing phenol rings and 
are divided into several group viz; phenolic acids, flavonoids and lignin. Amongst fruits like 
pears, grapes, apples and range of berries naturally contain good amounts of polyphenols (250–
400mg in 100 g). The most frequent phenolic acids are ferulic acid and caffeic acid that 
comprises of major phenolic compound in coffee and cereals, respectively. Most studied 
stilbene is resveratrol in red wine and grape products (Veberic et al., 2008). Other main dietary 
sources of natural phenolics comprises of chocolate, green tea and whole grains. Polyphenol 
contains abundant antioxidants in the diet and this act as natural scavengers for toxic elements 
and thus their intake has been directly connected with a reduced frequency of several hepatic 
ailments particularly hepatocellular carcinoma in humans (Turati et al., 2014). Phenolics also 
exhibit anti-inflammatory effects and influences hepatotoxicity through altered mechanisms 
discussed in details in the subsequent paragraph.  
Thus, herbal approach, an alternative to the conventional protocol with a touch of a therapeutic 
essence, remains a valid option. These strategies, in most cases, not only target the disease but 
also are with minimum side effects. Majority of the available synthetic  drugs for liver diseases 
are found to be strong pro-oxidant scavengers, but their long-term uses may cause 
inflammation (Rani et al., 2016;González-Ponce et al., 2018) and cancer. A noteworthy 
instance is the use of tiopronin, which increases the risk of liver injury ten folds with its long-
term treatment (Tang et al., 2014;Wan and Jiang, 2018). Another well-illustrated detrimental 
combination is ribavirin and interferon-α (IFN-α), a common medication in liver-related 
diseases, which is seen to aﬀect hepatitis C patients. Taking into consideration of such 
complications and high cost of available medicines, researchers are inclined to utilise natural 
products-based alternative medications for liver diseases, which will have better efficacy, cost-
effectiveness and lower or no toxicity (Zhang et al., 2013;Seeff et al., 2015).  
 
It is evident from the reports of the WHO (WHO 2016) that non-communicable diseases were 
the causes of 68% of all global death in 2012 (Figure 1), rising from 60% in2000. Hepatic 
complications have turned out to be multifactorial diseases that affected almost around 600 
million population in 2014 (Figure 2) and it is likely to amplify about 33% over the next two 
decades(Finkelstein et al., 2012;Dhilleswara Rao et al., 2017).  
 
PLEASE INSERT FIGURE 1 HERE 
Figure 1:Statistical representation of mortality (in percentage) from various diseases in 
human(Finkelstein et al., 2012).  
 
 
Hepatic ailment results in anomalous hypertrophy, expressed phenotypically with surplus 
adiposity, body fatness and brawny genetic correlation with its constituent to basal metabolic 
index and associated health hazard of obesity have also been reported(Locke et al., 
2015;Stender et al., 2017).  
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Figure 2: Occurrence and Prevalence of various liver diseases worldwide 
 
Various hepatic problems are encountered with a number of synthetic as well as plant-based 
drugs. Nexavar is a chemotherapeutic drug generally prescribed for complex renal carcinoma 
(Ravaud et al., 2016;Decker et al., 2017). It is additionally used to treat liver carcinoma. Known 
adverse effects of Nexavar include usually dry skin, itching, skin rash, nausea, vomiting, 
diarrhoea, patchy hair loss, loss of appetite, stomach pain, dry mouth, hoarseness and 
tiredness(Schmidinger and Bellmunt, 2010). Sorafenib is the first multi-kinase inhibitor (TKI) 
approved for the treatment of advanced hepatocellular cancer (HCC) metastatic renal cell 
cancer (RCC), and well-differentiated radioiodine-resistant thyroid cancer (DTC)(Monsuez et 
al., 2010). It demonstrates targeted activity on several families of receptor and non-receptor 
tyrosine kinases that is involved in angiogenesis, tumour growth and metastatic progression of 
cancer(Adnane et al., 2006). Sorafenib is a well-known antihepatotoxic drug available in 
market but the product of its metabolism has been seen to be toxic, which affects other parts of 
the body with long-term exposure  resulting in renal and pancreatic failure (Randrup Hansen 
et al., 2017;Balderramo et al., 2018). 
 
A few efficient varieties of herbal preparation like Liv-52, silymarin(Kolasani et al., 2017) and 
Stronger neomycin phages (SNMC) are in attendance against hepatic complications. All the 
candidates come up with notable complications. Silymarin is not found effective against 
chronic liver disease as it fails to modulate the metabolic condition of the liver along with 
cellular recovery. An effective Japanese preparation like SNMC(Ghiliyal and Bhatt, 2017) also 
fails to improve the clinical status with liver cirrhosis inspite of its prominent anti-inflammatory 
and cytoprotective efficacy. It is successfully used against hepatocellular carcinoma(Luo et al., 
2015). Liv-52 is used quite effectively against hepatic damages (Stickel and Hellerbrand, 
2015). However, it also fails to demonstrate clinical efficacy in alcoholic liver damages. 
Various research involving techniques with increasing efficacy of the phytochemicals like 
nanotechnology, proteomics, transcriptomics are evident and efforts are going on with herbal 
preparation are someway successful too (Patil et al., 2018). Taking the clue, from these 
interesting results, further attempts should be initiated to overcome all the odds of existing 
drugs, and an initiative may proceed with plant-based natural products. The plants are an 
enormous repository of bioactive secondary metabolites viz; alkaloids, flavonoids, phenol, etc. 
This review presents an account of studies on phenolics with its emphasis on it mechanism of 
towards hepatotoxicity. Emphasis have been given to understand various pathways through 
which phenolics exihibit their effecicacy. Furthermore a gene networking model has been 
constructed to have  a clear concise idea of natural phenolics contributing in mitigating various 
hepatic ailments.  
Methods 
With the aim to evaluate the actual sceneries of phenolic compounds for the treatment of 
various hepatic diseases, a search on the metabolic disease Library and PubMed has been 
performed matching the keywords “hepatic disease inhibitors treatment,” “target therapy,” and 
“Hepatic carcinoma,” limited to the English written literature, but with no restriction of time. 
It was examined and the titles of 202 relevant papers were retrieved. 
While performing through the search of abstracts and full-text research papers, all the unrelated 
and less important ones was discarded. Selection of the most recent and well-illustrated cited 
full-text articles were considered regarding similar types of research work from the same 
institute at different point of time. We have tried not counting the research papers, whose 
abstract or full-text is not obtainable. The references for significant and relevant papers have 
been further sought for other pertinent articles. After such an illustrative survey, around 160 
latest bioactivity reports of phenolic compounds mitigating hepatic diseases were brought into 
lights and also around 38 clinical trials have been retrieved gratifying the indispensable criteria 
for analysis. 
Gene networking model and connectivity model was developed by analyzing all the available 
reports on the hepatoprotective activity of the natural phenolics using the online software 
Cirrcon and Cytoscape version 3.6.1.  
 
Natural molecules as potent antihepatotoxic agent 
 
Plant secondary metabolites are well-known for their efficacy in the treatment as well as 
prevention of various fatal diseases. Plant phenolics, e.g., coumarins, flavonoids, lignans, 
stilbenoids, and tannins, have been studied extensively to provide scientific rationale behind 
their potential usage against various human ailments. Phenolics are the target group for this 
review article and subsequent discussions will revolve around exploring chemical nature, and 
modes of action of these compounds(Smith, 2017;Stander et al., 2017). 
 Phenolics constitute a major portion of all plant secondary metabolites discovered to 
date, and there are about 8000 of such compounds in both conjugated and free-form and 
distributed in all parts of the plant. Phenolics are generally biosynthesized from acetyl CoA, 
shikimate and amino acids(Cseke et al., 2016;Saltveit, 2017). Plant phenolics include simple 
phenols, phenolic acids, coumarins, lignans, flavonoids, diaryl-alkanoids, stilbenoids, 
proanthocyanins, and anthocyanins some alkaloids, and tannins.  
 
Natural product has been an integral part of medicine since ancient times where, around 400 
different species of plant and animal origins were then listed. According to the WHO, till now, 
plant based therapy are into action, where minerals, plants are common and easily available. 
Such accounts for around 88% of the population, where they depend on the natural product 
from their primary health care regime. Though the term ‘drug discovery’ sounds contemporary, 
yet the story of drug discovery dates back many centuries, where it has origin in its nature. 
Thus, present day uses of plants for ‘lead molecule’ discovery confirms its activity as active 
natural molecule or its structural analogue that can prove to be an ideal drug candidate.  
Natural products drug discovery is on air in recent years with a comeback in the main stream 
of drug discovery protocols. Such comeback is welcomed by academics and also pharma 
companies mainly due to inherent chemical diversities in natural products, and ease in 
identification and separation techniques. Noteworthy among natural products include alkaloid, 
carbohydrate, glycosides, terpenoids. Phenolics are most studied due to their antioxidant 
activities. The phenolic moiety is responsible for various pharmacological effects (Sarker and 
Nahar, 2007). 
Phenolic acids are mainly represented as derivatives of benzoic acid and cinnamic acid.  The 
methyl ester of the phenol ring imparts a pharmacophore, which is responsible for  interacting 
various protein targets present in cell membrane.  Gallic, ellagic, vallic, procatecutic, 
procoumaric and caffeic acids are important representative of hydroxyl benzoic acid hydroxyl 
cinnamic acid, which are the product of condensation reaction of phenols under 
sunlight(Ahmad et al., 2016;De Beer et al., 2017). Flavonoids on the other hand, biosynthesised 
from cinnamic acids, have two benzene rings (ring A and ring B), and apyrrole ring (ring C). 
Plant flavonoids are generally classified into flavan, flavanone, flavanol, flavone and flavonols 
(Sarker and Nahar, 2007).Often there are prenylations, glycosidations and conjugation with 
other ring systems or natural skeletons as well as dimerisations and oligomerisations diversify 
flavonoid structures and provide new pharmacophores. Quercetin, hesperidin, diosmetic, 
myrectin and kaempferol are just a few notable examples imparting biological 
properties(Hussain, 2016;Brodowska, 2017). 
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Figure 3: Structures of various groups of Phenolic compounds (Hussain, 2016;Mandal et al., 
2017;Xi et al., 2018) 
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Figure 4: Flowchart showing various descendants of the Phenolic groups. 
 
Anthocyanidins and anthocyanins are normally plant pigments. Anthocyanidins are 
grouped into 3-hydroxyanthocyanidins, 3-deoxyanthocyanidins, and O-methylated 
anthocyanidins. On the other hand, anthocyanins are in the forms of anthocyanidin glycosides 
and acylated anthocyanins (Sarker and Nahar, 2007). The most common types of 
anthocyanidins are cyanidin, delphinidin, pelargonidin, peonidin, petunidin, and 
malvidin(Wallace and Giusti, 2015;Chorfa et al., 2016;Makila et al., 2016;Stein-Chisholm et 
al., 2017). The site of glycosylation in anthocyanidins is usually at C-3(Kay et al., 
2017;Rodriguez-Amaya, 2018;Zhang et al., 2018).Acylated anthocyanins are presented with 
p-coumaric acid, ferulic acid and caffeic acid with attached sugar molecules, in addition to 
simple acetyl group (Sigurdson et al., 2017;Zhao et al., 2017). 
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Figures 5 and 6: Structures of some bioactive phenolics acting as hepatoprotective compounds  
 
 
Phenols are important as prospective drug leads 
Phenolic compounds are known for their diverse chemical structures, common antioxidant and 
specific anti-inflammatory actions. They offer protection against oxidative damages by 
donating hydrogen or electron to free radicals and thus in this process they aid in stabilizing 
cell membrane networks and inhibit the formation and expression of inflammatory cytokines 
like tumour necrosis factor alpha (TNF-α), Transforming Growth Factor beta (TGF-β) and 
varieties of interleukins (IL-6, IL-2, IL-8)(Parhiz et al., 2015;Taofiq et al., 2015;Zhang and 
Tsao, 2016;Zhen et al., 2016).  
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Figure 7: Metabolism of phenols in the living system. The metabolism of the dietary components 
rich in phenols is easily absorbed by various part of the animal body where the small intestine process 
and deviates the potent part to hepatic cells and remains are hydrolysed in colon and excreted via 
faeces. Simultaneously, a part of it is methylated in kidney through liver and the last remains are 
excreted through urination. The red arrows mark is used to show the various route of metabolism of 
phenols. 
To exert any pharmacological or biological actions, phenolic compounds initially areabsorbed in the 
gastrointestinal tract (GIT) and thus make it bioavailable to circulating system. In the case of inadequate 
or no absorption through the GIT, they undergo biotransformation in the colon with the help of resident 
microbiota culture (Filannino et al., 2015;Heleno et al., 2015;Gómez-Juaristi et al., 2018). Phenolic 
compounds offer health benefits including treating cancer, oxidative damage and inflammation. 
Literature supports their effectiveness against chronic pathogenic conditions like neurodegenerative and 
cardiovascular diseases (Heleno et al., 2015;Rangel-Huerta et al., 2015;Domínguez-Avila et al., 2017). 
 Detailed mechanism of hepatoprotection 
When the liver is exposed to alcohol, drugs, and pollutants, its progression towards damage 
initiates hepato steatosis, fibrosis and cirrhosis. This exposure results in the death of 
hepatocytes and as a consequence, level of various liver enzymes and metabolites are altered 
indicating the anomaly (Sheriff et al., 2017;Balderramo et al., 2018;Hu et al., 2018). 
Hepatocytes may be injured in various circumstances like toxic environment, alcohol, virus, 
fatty acid metabolism or chronic antibiotics exposure. Transaminases and glutathione are 
reported to be prime candidates’ marker in the line up metabolism of bile when hepatocytes 
are damaged. The clinical condition of the hepatic environment can further be measured with 
level of alkaline phosphatase (a key hepatic enzyme) in the serum(Culver, 2016). 
Under these surroundings, scarring tissues tries to replace the damages, and thus compromising 
with the vital liver functions like drug detoxification, secretion of the protein, albumin 
production etc(Anand and Garg, 2015;Baker, 2015). Metabolism, detoxification, and clearing 
of many drugs are blocked with the impaired liver(Bhattacharyya et al., 2014;Sheriff et al., 
2017). Although there are several cited important bioactivity of phenolic compounds, the 
current discussion will primarily encircle around exploring detailed mechanisms of actions, 
and further contributions of phenolics against various liver damages. 
 
Oxidative stress and hepatotoxicity: The liver being a keen partner and prime neighbour of the 
GIT is usually exposed to toxicity arising from the broad range of drugs, xenobiotics and also 
the stress mediated by reactive radicals formed during uncontrollable oxidation processes. 
Being a frequent target of such complex substances, and possessing unique metabolism system, 
it hampers itself in the process of breaking them into simpler ones (Cederbaum, 2017b). For 
instances, the large amount of bile acid produced during oxidation of ethanol produces 
hepatocellular apoptosis by exciting Fas, an apoptotic element, expressing it from in the plasma 
membrane triggering apoptosis resulting in cholestatic disease(Cederbaum, 2017). The liver 
also efficiently expresses main cytochrome P450 isoforms in response to various xenobiotics. 
CYP2E1 is one such that generates reactive oxygen family, activates toxicologically central 
intermediates, and may be the critical alleyway by which these toxic chemical groups cause 
oxidative stress. Further, kupffer cell, a specialized cell in liver is activated in this process of 
metabolism. Both Kupffer cell activation and infiltration of neutrophil release reactive oxygen 
species (ROS), a range of inflammatory chemokines increasing the fold of hepatotoxicity 
(Wang, 2015;Ahadpour et al., 2016). 
 In vivo and in vitro studies have demonstrated the promising preventive and 
therapeutic effects of plant phenolics in a range of liver diseases. Translational studies are 
extremely vital and indispensable for the application of phenolics in human with liver diseases. 
Although literature in the PubMed database about clinical trials of phenolics in liver diseases 
are limited, encouraging beneficial effects of these phenols have been demonstrated, 
particularly in Non-Alcoholic Fatty Liver Disease (NAFLD). When working with the high fed 
diet, the AKT signal molecule responsible for fat metabolism is mutated in the model systems, 
placebo-inhibited trial of a purified form of anthocyanin in NAFLD patients, treating with the 
fixed amount of purified anthocyanin for three months significantly improved insulin 
resistance, in liver injury(Zhang et al., 2015a), and clinical evolution in such patients (Bischoff 
et al., 2018). In another double-blind clinical trial, dihydromyricetin, the main active ingredient 
of Ampelopsis grossedentata, improved glucose and lipid metabolism and showed anti-
inflammatory effects in NAFLD(Chen et al., 2015b;Hou et al., 2015). When working with the 
hepatotoxic model system, the mice cohort which was treated with thioamino acetic acid 
showed significant recovery in its MAPK and AMPK level, the two important pathways, which 
imparts cAMP and are a source of energy to the hepatocytes. This recovery waswitnessed when 
a most studied flavonoid, curcumin was administered at a dose of 118μg/kg b.wt.  
 
 
Alcohol and hepatotoxicity: Alcohol hinders the functional aspects of various tissue 
components and hepatocytes in particular. Alcohol diffuses crossing the membrane barrier and 
distributes throughout the cell and tissue system, interacting with the major proteins and 
cellular component present in it (Li et al., 2016). Development of toxic molecules like reactive 
oxygen species (ROS) is another pessimistic upshot of alcohol. In addition to ROS, it also 
produces acetaldehyde and nitric oxides, an extremely reactive and toxic by-product that chip 
into tissue damage (Madrigal-Santillán et al., 2015;Marshall, 2016). Nitric oxide (NO) is 
recognized to manage mitochondrial respiration and biogenesis amongst organelle. Under 
conditions of alcohol-mediated hepatic complications, mitochondrial respiration hindered, and 
inturn hypoxia occurs. Simultaneously, nuclear factor-kappa β (NF-κβ), a transcription factor 
activation takes place, where it binds to iNOS promoter, an important NO and aggravate the 
expression of iNOS(Iwakiri and Kim, 2015;Starkel et al., 2016). This entire environment 
together amplifies the expression of inducible nitric oxide synthase (iNOS).iNOS joins hands 
in inducing hepatic fibrosis and expression of inflammatory cytokines(Tacke and 
Zimmermann, 2014;Cassini-Vieira et al., 2015).  iNOS increases two other factors in this 
process. Hypoxia-inducible factor-1 and its gene expression aids in various connected hepatic 
anomalies viz; inhibition of mitochondrial respiration, impairment of mitochondrial fatty acid 
β-oxidation and mitochondrial DNA damage (Chang et al., 2015;Suraweera et al., 2015).  
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Figure 8: Detailed Mechanism of generation of hepatotoxicity 
 
When the elicitors like alcohol, CCl4 enters the cell membrane they instigate various metabolic reactions 
activating the CYP systems viz; activating the endogenous glutathione enzyme, hydrogen peroxide. Formation of 
the reactive oxygen species are responsible for the lipid peroxidation reaction.A conjugation reaction parallel 
takes place resulting in the deterioration in the ATP levels and elevation in the caspases levels. These clinical 
manifestation leads to the building up of hepatotoxicity and induces apoptosis. The nucleus also takes part in such 
build up by upregulating various transcription factors associated with inflammation. The adhesion molecules 
present in the cell membrane further creates hepatic fibrotic response by coupling with various reactive oxygen 
species. The activated Kupffer cells on the other hand, further activate the prostaglandin by COX-2 and thus 
increases the cytokines level in the blood. These reactions are catalyzed by arachidonic acid. All such atrocities 
give rise to associated diseases with inflammation and further fibrogenesis. Hepatic necrosis is another condition 
imparted by the activated neutrophil which are though inactive during a normal state, increases its number when 
the cytokine level increases in the blood. The fatal condition, hepatic cirrhosis is also encountered from 
hepatotoxicity, which is the additive effect of the prolonged inflammation and interaction with the ROS generation.  
 
 
Phenolics possess immense potentials in regulating the inflammatory cytokines, which 
are expressed in clinical conditions such as alcoholic liver diseases (Wan and Jiang, 2018;Xu 
et al., 2018). Puerarin, a known isoflavone, can excite the AMP-activated protein kinase 
(AMPK) phosphorylation in H4IIE cell lines suppressing the (m TOR) target proteins and 4E-
binding protein (Zhao et al., 2016). This strategy aids in ameliorating the alcohol-based 
hepatotoxicity. Puerarin can also alleviate the hepatic necrosis due to its role in the AMPK 
pathway activation, scavenging activity and lipid peroxidation inhibition (Wang et al., 2018a).  
 
PLEASE INSERT FIGURE 9 HERE 
 
Figure 9: Alcohol mediated Hepatotoxicity. Hepatotoxicity caused by increased production of 
ROS; due to alcohol damages antioxidant defences and mitochondrial function as well as structure. It 
leads to liver inflammation, fibrosis and steatosis. Cellular responses, which are sturdily involved in 
Kupffer cell may also activated due to action of ROS which contribute to an increase inflammatory 
responses resulting liver injury. Furthermore, activated Kupffer cells release ROS and cytokines that 
are crucial forHSC activation and to induce the pro-fibrogenic pathway. 
 
 
Hepatotoxicity and non-alcoholic liver disease: Majority of the metabolic disorders and their 
physiology related to hepatotoxicity has been studied over the years. Where sharp and clear 
possible elements responsible for chemical-induced toxicity, enzymes and protein-induced 
complications are considered, yet a fair amount of diseases related to metabolism yet leftovers 
unidentiﬁed. Such prognostic parameters include blood pressure, abdominal obesity or may be 
hyperglycaemia. They are collectively termed as the non-alcoholic fatty liver diseases 
(NAFLD)(Chalasani et al., 2018).This clinical situation is one of the most familiar and dormant 
forms of liver diseases, which accounts for the preliminary stage, but when left untreated this 
results in the inflammation and subsequently can even lead to serious ﬁbrosis and even 
hepatocellular carcinoma (HCC) with high rates of mortality(Chen et al., 2015a) 
 
Until now, the main drugs for the treatment of NAFLD in the clinics are lipid regulating 
agents such as statins, which are not only toxic but also aggravate the deposition of lipids in 
the liver, leading to serious liver injury(Arguello et al., 2015). Phenolics such as baicalin, 
epicatechin and apigenin (Figure 5) have been reported to protect the liver from NAFLD, which 
are associated with their eﬀects on insulin resistance and signaling way related to anti-
inﬂammation as well as antioxidant action (Sen and Chakraborty, 2017;Wan and Jiang, 2018).  
 
Phenolic compounds can significantly regulate these NAFLD conditions. Apigenin, a 
flavone, is a well-studied phenolic compound that can check the lipid accumulation and 
oxidative stress induced by high-fat diet. It can abridge the inﬂammatory mediators but can 
simultaneously amplify various endogenous antioxidative enzymes actions like superoxide 
dismutase, glutathione peroxidase in the liver (Feng et al., 2017;Vergani et al., 
2017).Dihydromyricetin, another important phenolics exhibit its therapeutic effect by the 
improvement of glucose and lipid metabolism in patients with NAFLD, by blocking the 
phosphatidyl inositol 3-kinase, NF-κβ signaling pathway(Chen et al., 2015b). 
 
Hepatotoxicity and inflammation: Liver inflammation is a state of the reaction in which the 
liver tissues send a constant stimulus whether acute or chronic, in response to extrinsic and 
intrinsic factors hampering the liver status. Acute inflammation is a localized affair, where the 
liver tries to regain its previous configuration. It is the first line of defence, but when the liver 
cannot check these associated level of lymphocytes, vascular proliferation and tissue 
destruction become chronic and ultimately leads fibrotic condition (Pawlak et al., 2015;Leyva-
López et al., 2016). 
During such chronic conditions, specialized cells such as macrophages recruit more of 
the inflammatory mediators including interleukins, tumour necrosis factor (TNF)-α(Seki and 
Schwabe, 2015;Williams et al., 2016). This amplification altogether results in such a more 
complex state that it leads to many degenerative diseases including most severe cirrhosis and 
hepatic carcinoma(Czaja, 2014). For this reason, slowing down the inflammation process 
becomes essential. Initially, non-steroidal anti-inflammatory drugs (NSAIDs) are prescribed 
but the associated side effects include mild gastritis, renal failure and at times allergy due to 
hypersensitivity(Pawlak et al., 2015) 
Recent information on hepatic inflammation demonstrated the role of phenolics in 
protecting such inflammation. Phenolic compounds like hesperidin can act against 
inflammation by downregulating liver enzyme biomarkers such as aspartate amino transferase 
(AST) and alanine aminotransferase (ALT) primarily. It can also hold back oxidative stress 
and activation of T cells, which is a prime instigator of inﬂammation (Li et al., 2014). 
Hesperidin, a common Citrus flavonoid, further aids in the management of various 
proinflammatory recruiters viz; NF-κβ and α smooth muscle actin (α-SMA). Another well-
known flavone, silymarin, is also a subclass of the family of phenolic compounds that works 
in patients with chronic hepatic carcinoma (González-Gallego et al., 2014). 
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Figure 10: Protective effect of phenols in various metabolic pathways in liver diseases. The 
upward arrow indicating upregulation and down arrow indicating downregulation of the enzymes. 
 
 
Regulation of gene expression by phenolics 
 
The chemical nature, physical properties and dose ratio of a particular drug along within 
dividual's gene expression profile, antioxidant status and the capacity for regeneration are also 
crucial for cell injury. Several mechanisms are involved in the initiation of liver cell damage 
and aggravate ongoing injury processes(Guan et al., 2014;Ju and Tacke, 2016). Dysfunction of 
these vital cell organelles results in impairment of dynamic equilibrium in homeostatic 
condition, thus resulting in intracellular oxidative stress with excessive formation of reactive 
oxygen species(Cannistrà et al., 2016;Ramachandran et al., 2018). Major causes of the 
hepatotoxic reactions by drugs are elevated ROS generation, oxidative stress and suppressed 
immune responses. Hepatotoxicity remains a major cause of drug withdrawal from the market. 
Recent examples in the USA and Europe are ximelagatran, nefazodone, nimesulide, ebrotidine, 
trovafloxacin, troglitazone, bromfenac, and so forth. 
Gene-metabolic networks are an advanced mode to construct a network with genes and metabolites specifically deregulated in different liver 
disease phenotypes. It compactly gives an overview of  genes of interest, representative gene subsets that were involved in regulated signaling 
pathways, including tumor necrosis factor(TNF), P53, NF-κB, chemokine, peroxisome proliferator activated receptor (PPAR) and Toll-like 
receptor (TLR) signaling pathways associated with the physiology of various hepatic disease. Detailed information for the clinical status and 
associated genes in the hepatotoxicity are summarized in gene networking model Figure 12. Gene regulation of a few bioactive phytocompounds 
is discussed below in Table 1 
 
Table1: List of a few potent natural phenolics and their mode of action imparting hepatoprotective activity 
Sl No. Compound Name Sub Category 
 
Type of Liver disease 
Structure Mode of Action Reference 
1 Apigenin Flavone 
Hepatic 
ischemia/reperfusion 
O
O OH
OH
OH
 
Up regulating 
BCL-2 levels 
(Tsaroucha et al., 2016) 
2. Caffeic acid Phenolic acids Diabetic Liver injury 
O
OH
OH OH
 
lipid peroxidation 
and antioxidant 
enzymes 
(Yilmaz et al., 2004) 
3. Catechin Flavonols Hepatic tissue injury 
O
OH
OH
OH
OH
OH
 
antifibrotic and 
antioxidative 
(Kobayashi et al., 2010) 
4. Curcumin Curcuminoids 
Non-alcoholic 
steatohepatitis 
O
OH
O
O
OH
O
 
Immunomodulato
ry 
(Nafisi et al., 2009) 
5. Epicatechin Flavonoids Diabetic Liver injury 
 
Lipid 
peroxidation and 
antioxidant 
enzymes 
 Effects of (–)-
epicatechin, a 
flavonoid on lipid 
peroxidation and 
antioxidants 
streptozotocin-
induced diabetic 
(Terao et al., 1994) 
O
OH
OH
OH
OH
OH
liver, kidney and 
heart.   
6. Ferulic acid Phenolic acids 
Carbon tetrachloride 
(CCl4)-induced acute 
liver injury 
CH3O
O
OH
OH
 
antioxidant, 
anticancer, and 
anti-inflammatory 
(Kim et al., 2011) 
7. Hyperoside Flavonol Liver injury 
O
O OH
OH
O
O
OH
OH
OH
OH
OH
OH
 
Enhancement of 
APAP clearance 
(Choi et al., 2011) 
8. Icariin 
Prenylated 
flavonol 
glycoside 
(Flavonoid) 
Hepatic fibrosis 
O O
OH
HO OH
OHO
O
O
O
HO
O
OH
OHHO
 
Anti-angiogenic 
and anti-
autophagic 
(Algandaby et al., 2017) 
9. Magnolol Neo-lignan 
Immune-related liver 
fibrosis 
CH2
OH
CH2
OH
 
Anti-
inflammatory and 
antioxidant 
effects 
(Ogata et al., 1997;Lin et 
al., 2001) 
10. Morin Flavonoid Hepatic fibrosis 
 
 
Suppressing 
canonical NF-
κBsignaling. 
(Sivaramakrishnan and 
Devaraj, 
2009;MadanKumar et 
al., 2014) 
11. Naringenin Flavanone Hepatic inflammation 
O
O OH
OH
OH  
activation of an 
Nrf2-mediated 
pathway 
(Totta et al., 2004;Yen et 
al., 2009) 
12.  Resveratrol Stilbenoid Alcoholic fatty liver 
OH
OH
OH
 
Inhibition   of 
sirtuin 1 (SIRT1) 
and AMP-
activated kinase 
(AMPK) 
(Frémont, 2000;Baur and 
Sinclair, 2006) 
OH OH
O
O OH
OH
OH
13. Wogonoside Flavonoid Hepatic fibrosis 
CH3
O
O
OOH
O
O
O OH
OH
OH
OH
 
Antifibrotic (Yang et al., 2013) 
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Figure 11: Gene networking showing hepatotoxicity mediated gene expression and subsequent mode of action of various natural products. This 
network was generated by a software Cytoscape version 3.6.1. 
 
 
 
 
 
 
 
  
 
 
TABLE 2: Table showing various hepatic diseases and various genes and metabolites associated with it 
COMPOUND 
HEPATIC 
DISEASES 
CLINICAL 
CONDITION 
TARGET FAMILY 
REGULATIO
N 
INVOLVED IN 
EXPRESSION 
 
 
REFERENCES  
Amentoflavone microsomal lipid 
peroxidation 
Fatty liver disease COX-2  inflammatory 
mediators  
inhibition AP-1( 
downregulation) 
(Arannilewa et al., 
2006;Yadav et al., 
2016) 
Baicalein hepatic apoptosis, 
inflammatory liver 
injury 
acute liver 
apoptosis  
IκBα, ERK and 
JNK 
inflammatory 
mediators  
downregulation NF-β (down 
regulate) 
(Meng et al., 2018) 
(Liu et al., 2015) 
Caffeic acid  inflammatory liver 
injury 
acute liver failure c-FLIPL, XIAP 
and cIAP2 
proteins 
apoptotic protein  activation NF-β (down 
regulate) 
(Shi et al., 2018) 
 inflammatory liver 
injury 
acute liver failure c-FLIPL, XIAP 
and cIAP2 
proteins 
apoptotic protein  activation TNF-α (down 
regulate) 
(Wang et al., 2018b) 
hepatic lipid 
peroxidation  
Alcoholic fatty liver 
disease (AFLD) 
glutathione 
reductase(GSH) 
antioxidant 
enzymes 
increase microsomal 
ethanol‐oxidizing 
system( increase) 
(Chu et al., 2015) 
Clofibrate 
hepatic excessive 
proliferation 
HCV-mediated 
hepatocellular 
carcinoma (HCC) 
Cyp4a10 and 
Cyp4a14 
mRNA expression 
of factors 
increase 
Acox1, Ech1, and 
Ehhadh 
(increased) 
 
Lipe and Pnpla2 
(increased) 
(Moody and Reddy, 
1978;Bogdanska et 
al., 2018) 
Galangin microsomal lipid 
peroxidation 
Fatty liver disease COX-2 and iNOS inflammatory 
mediators  
inhibition NF-κB 
(downregulation) 
(Ren et al., 2016) 
Gardenin D microsomal lipid 
peroxidation 
Fatty liver disease COX-2  inflammatory 
mediators  
inhibition AP-1( 
downregulation 
(Toppo et al., 2017) 
Glabridin chronic 
inflammatory liver 
disease 
acute or chronic 
hepatitis and  
PPARγ 
(peroxisome 
proliferator-
   (Li et al., 2018) 
(Thakur and Raj, 
2017) 
activated receptor 
gamma) 
chronic 
inflammatory liver 
disease 
hepatic steatosis CCAAT enhancer 
binding protein 
alpha (CEBPα) 
inflammatory 
mediators  
downregulation Phosphoenol 
pyruvate   
carboxykinase 
and  
glucose 6-
phosphatase 
(downregulate) 
(Namazi et al., 2017) 
 
  cytochrome c,    (Lin et al., 2017) 
Hispidulin hepatic lipid 
peroxidation  
Alcoholic fatty liver 
disease (AFLD) 
glutathione 
reductase(GSH) 
antioxidant 
enzymes 
increase microsomal 
ethanol‐oxidizing 
system( increase) 
(Wu and Xu, 
2016;Han et al., 
2018) 
Icariin hepatic excessive 
proliferation 
HCV-mediated 
hepatocellular  
carcinoma (HCC) 
PPARα mRNA expression 
of factors  
inhibition Cpt1a, Acat1, 
Acad1 and 
Hmgcs2 
(increased) 
(Lee et al., 1995;Lu 
et al., 2014) 
Kaempferol 
 
fatty liver diseases liver fibrosis  iNOS, COX-
2 and CRP 
protein level 
inflammatory 
mediators  
downregulation NF-β (down 
regulate) 
(García-Mediavilla et 
al., 2007) 
 (Kashyap et al., 
2017) 
fatty liver diseases liver fibrosis   (IRS-1)  (IKKα) 
and (IKKβ). 
inflammatory 
mediators  
downregulation kappa-β (NF-κB), 
(TNF-α) and (IL-
6) (down 
regulate) 
(Dong et al., 2017) 
Kolaviron liver inflammation primary biliary 
cirrhosis 
COX-2 and iNOS inflammatory 
mediators  
inhibition NF-κB and AP-
1 (downregulation
) 
(Adaramoye and 
Lawal, 
2015;Awogbindin et 
al., 2015) 
Liquiritigenin 
hepatic failure 
 
liver cirrhosis and 
hepatocellular 
carcinoma  
PGC-1α, ND1, 
and Bcl-x 
metastasis 
mediators  
upregulation apoptosis 
(downregulate) 
(Yu et al., 2015;Li et 
al., 2018) 
liver cirrhosis and 
hepatocellular 
carcinoma  
AMPK  activation   FXR  (promote 
expression) 
(Teng et al., 2016) 
Luteolin 
 
liver injury 
fatty liver 
development 
SREBP-1c transcriptional 
factors  
activation cholesterol 
biosynthesis 
(activation) 
(Seydi et al., 2018) 
hepatic steatosis  AMPK  energy sensor activation ATP-producing 
catabolic 
pathways 
(Lee et al., 
2006;Cummins et al., 
2018) 
    , such as FA 
oxidation(activati
on) 
(Kwon and Choi, 
2018) 
liver cirrhosis and 
hepatocellular 
carcinoma  
 iNOS  inflammatory 
mediators  
downregulation NF-ƙβ (down 
regulate) 
(Jung et al., 2017) 
hepatic diseases hepatic fibrosis  AKT, mTOR  and 
p70S6K 
energy sensor activation TGFβ1‐simulated 
phosphorylation 
of 
AKT(downregulat
e0 
(Domitrović et al., 
2009;Panahi et al., 
2018;Wan and Jiang, 
2018) 
 
Morin microsomal lipid 
peroxidation 
Fatty liver disease COX-2 and iNOS inflammatory 
mediators  
inhibition NF-κB 
(downregulation) 
(Fang et al., 
2003;Shankari et al., 
2010) 
Naringenin  HIV-1/HCV co-
infective liver 
disease 
HCV-mediated 
hepatocellular  
ACSL4, GNMT, 
IFI27, and 
miR122 
 downregulation NF-ƙβ (down 
regulate) 
(Jain et al., 2011) 
(Hernández-Aquino 
and Muriel, 2018) 
 carcinoma (HCC)    TNF-α (down 
regulate) 
(Hernández-Aquino 
and Muriel, 2018) 
 Nobiletin chronic 
inflammatory liver 
disease 
liver cancer PPARα and 
PGC1α 
 inhibiting 
adhesion, 
 (Kim et al., 2017) 
(He et al., 2016) 
(Wu et al., 2018) 
chronic 
inflammatory liver 
disease 
liver cancer ERK and 
PI3K/Akt 
metastasis 
mediators  
 invasion, and 
migration 
iNOS and COX-
2, TNF-α (down 
regulate) 
(Yuk et al., 2018) 
Prunetin 
 
lipid accumulation 
in the liver  
Hyperlipidemia  AMPK metastasis 
mediators  
activation HMG-CoA R 
(inactivates) 
(Wei et al., 2018) 
adipogenesis in the 
liver  
Fatty liver disease PPARγ, C/EBPα, 
SREBP, aP2, 
adipogenic genes  inhibition  LDLR (promote 
expression) 
(Chen et al., 
1998;Ding et al., 
2016) 
   LPL adiponectin, 
and leptin 
   (Zhang et al., 2007) 
adipogenesis in the 
liver  
Fatty liver disease SREBP, PPARγ, 
LXR, and HMG-
CoA 
lipid metabolism-
related genes 
suppressed LDLR (promote 
expression) 
(Walle, 2007) 
adipogenesis in the 
liver  
Fatty liver disease adipoR1, adipoR2 adiponectin 
receptors  
induction AMPK induction  (Wei et al., 2018) 
Quercetin   iNOS, COX-
2 and CRP 
protein level 
inflammatory 
mediators  
downregulation NF-ƙβ (down 
regulate) 
(Kumar et al., 2016) 
(Gupta et al., 2010) 
Rutin hepatic diseases Hepatocarcinoma  PPARα, AMPK 
activity,  
metastasis 
mediators  
downregulation SREBP‐1(down 
regulate) 
 
(Pan et al., 2014) fatty liver disease 
obesity 
hyperlipidemia 
hepatic diseases Hepatocarcinoma  p53 and CYP 
2E1  
reactive metabolic  downregulation ROS (down 
regulate) 
(Mansour et al., 
2017;Nazeri et al., 
2017) 
fatty liver disease trichloromethyl 
radicals 
liver cirrhosis trichloromethyl 
radicals 
Silibin microsomal lipid 
peroxidation 
Fatty liver disease COX-2 and iNOS inflammatory 
mediators  
inhibition NF-κB 
(downregulation) 
(YU and REN, 
2008;Hernandez-
Rodas et al., 
2015)Younossi et al., 
2017 
Silymarin hepatic 
centrilobular 
necrosis 
paracetamol toxicity glutathione 
reductase (GSH) 
antioxidant 
enzymes 
increase microsomal 
ethanol‐oxidizing 
system( increase) 
(Lieber et al., 
2003;Ni and Wang, 
2016;Abenavoli et 
al., 2018) 
steatohepatitis, 
hepatic fibrosis 
(Boari et al., 
1981;Pradhan and 
  
Girish, 2006;Vargas-
Mendoza et al., 
2014) 
Steatosis chronic hepatitis C COX-2 and iNOS inflammatory 
mediators  
inhibition NF-κB and AP-
1 (downregulation
) 
(Saller et al., 
2001;Jose et al., 
2011) 
Tangeretin chronic 
inflammatory liver 
disease 
primary biliary 
cirrhosis 
Pregnane X 
Receptor(PXR) 
nuclear receptor 
gene 
activation NF-β (down 
regulate) 
(Omar et al., 2016) 
(Di Carlo et al., 
1999) 
Liver fibrosis TNF-α (down 
regulate) 
(Fracanzani et al., 
2008) 
Tricin liver inflammation liver cirrhosis ERK1/2 and Akt downstream 
signaling molecules 
supress  blocking cell 
cycle progression 
(Arulselvan et al., 
2016)(Seki et al., 
2012) 
hepatic diseases hepatocellular 
carcinoma 
(PDGF)‐BB platelet‐derived 
growth factor 
inhibition blocking cell 
cycle progression 
(Malvicini et al., 
2018) 
 Apiginin: Apigenin, a plant flavone, can improve hepatic health during severe liver disease 
conditions by down-regulating Nrf2-signalling and up-regulatingBCL-2 apoptotic pathway 
(Tsaroucha et al., 2016) 
Caffeic acid: It is chemically 3,4-dihydroxycinnamic acid that occurs in the diet like fruits, 
green tea, wine, coffee bean components. Caffeic acid showed potential antioxidant and anti-
inflammatory properties and is effective in treating major liver hitches(Kim et al., 2018). It can 
modulate the expression of kelch-like ECH-associated protein-1(Keap1), a hepatic carcinoma 
factor, by interacting with Nrf2 binding site and restraining it from binding to Keap1 and 
elevating the expressions of vital antioxidative signals like HO-1(Yang et al., 2017). 
Catechin: Catechin from green tea extracts, selective seeds and fruits. It is categorized by the 
presence of a hydroxyl moiety at C3, C5 and C7 position of at A ring, and again in C3 and C4 
of the B ring. Catechin with anti-hyperlipidemic property helps in treating diverse clinical 
condition associated with non-alcoholic fatty liver diseases where abnormality in protein and 
lipid metabolism plays the prime role in pathophysiology of the liver(Sun et al., 2015;Pezeshki 
et al., 2016). 
 
Curcumin: It exerts its protective and therapeutic effects in oxidative coupled liver diseases 
by suppressing proinflammatory cytokines, lipid peroxidation products, hepatic stellate cells, 
and Akt activation. Curcumin ameliorates oxidative stress induced expression of Nrf2, SOD, 
CAT and GSH. Curcumin acts as a free-radical scavenger over the activity of different kinds 
of ROS via its active phenolic pharmacophore, β-diketone and methoxy group (Nabavi et al., 
2014).  
Epicatechin: It is a flavan-3-ol found in edible plant products like cocoa and other varieties of 
plant foods. Epicatechin plays an important role in lipid metabolism in fatty liver condition and 
hypercholesterimia(Cordero-Herrera et al., 2015). It can down-regulate important liver 
enzymes like SGPT and SGOT, which increases its liver anomalies(Shanmugam et al., 2017). 
Ferulic acid: It is the most abundant phenolic acid in plants that has potent antioxidant ability 
to freeze the activity of the free radicals like NO, O2
-. It exhibits prevailing anticholestatic 
action against liver cholestasis by inhibiting extracellular matrix related gene expression and 
also by disruption of the Smad signaling pathways and extracellular signal-regulated 
kinases(Gerin et al., 2016). It sometimes activate the AMPK or the MAPK signaling pathway 
by enhancing lipid metabolism(Cheng et al., 2018). Several reports also confirmed the mode 
of action of ferulic acid is mediated by regulating the expression of several physiological 
factors viz; PPAR-α, CPT-1α towards lipid oxidation and this action is very important in 
treating with fatty liver diseases (Kim et al., 2011).  
Hyperoside: It is a significant flavonoid that can fuel up the expression of diverse endogenous 
antioxidant enzymes and can quench free radicals formed during the metabolism of xenobiotics 
in the liver. Further, the capacity of hyperoside to regulate detoxifying enzymes phase II makes 
it potent as these enzymes are the prerequisite for liver during the initial round of oxidation. It 
helps in mitigating liver fibrosis by activating the Nrf2 signaling pathway, meant for 
neutralizing oxidants, when studied in CCl4-induced hepatotoxicity (Wang et al., 2016;Xie et 
al., 2016;Zou et al., 2017). 
Iccarin: It is reported from genus Epimediumand has been shown to delay the fibronectin and 
collagen accumulation in renal interstitial tissues and mesengial cells of rat model (Algandaby 
et al., 2017). Several published reports confirmed its protective role in inflammation blocking 
TNF-α and IFN-γ signalling pathway(Sinha et al., 2016).Other important protective actions of 
iccarin comprises of modulating expression of toll-like receptor and inhibition of the mitogen 
activated protein kinase (MAPK) (Mochizuki et al., 2002). 
Magnolol: Magnolol from Magnolia officinalis is an important phenolic compound that 
maintains the oxidative balance during hepatotoxicity in galactosamine-injured mice models. 
Magnolin, another phenolics from same plant was reported to have ameliorating activity in 
lipid build up, insulin resistance and also in hepatic inflammation, when hepatocytes are 
exposed to free fatty acid in vitro(Tian et al., 2018). 
 
Morin: Morin,a naturally occurring 2′,3,4′5,7-penta-hydroxyflavone, present in mulberry, 
tartary buckwheat, jackfruit, green tea, orange and in many dietary plants. It exerts beneficial 
effects on metabolism by suppressing canonical NF-Κβ signaling. (Caselli et al., 2016; Sinha 
et al., 2016). 
Naringenin: Naringenin, a natural flavonoid, possesses antioxidant, anticancer and anti-
inflammatory activity(Chtourou et al., 2015). Naringenin though exhibits very little antioxidant 
action directly as a scavenger, yet  it helps inupregulating of Nrf2 pathway and thus uphold the normal 
redox of the cell even in clinical conditions where prooxidants and reactive oxygens  are formed as a of 
damage mechanism in hepatocytes ,(Esmaeili and Alilou, 2014). 
Resveratol: Resveratrol, a 3,5,4′-trihydroxystilbene polyphenolic compound, is available in 
edible plants and selected fruits like grapes. It can control a specialized mammalian homolog, 
sirtuins (SIRT) (Andrade et al., 2014). Over expression of this homolog helps in treating non-
alcoholic related fatty liver disease by regulation lipogenesis. Resveratrol is associated with  
considerable reduction in various liver enzymes, cytokines and also transcriptional factors like 
nuclear factor κB. It alleviates the nuclear factor-κB (NF-κB) expression following  the 
stimulation of its inhibitor IκBα (Zhang et al., 2015b).  
Wogoloside: It is another flavone that imparts hepatoprotective activity via different facilitating 
lipid metabolism by increasing oxidation process. AMPK signalling to bestow its effectiveness 
by various modules (Wang et al., 2015) 
 PLEASE INSERT FIGURE 12 HERE 
Figure 12: gene-modelling showing various hepatic diseases and associated genes with it. A tool 
named Circus on shiny Circos server generated this image. The blue band is showing various genes 
responsible for pathophysiological conditions, the green showing various hepatic complications and 
the red band shows the bioactive natural compounds possessive hepatoprotective activity. Various 
shades indicating the degree of relatedness between the various bands. 
Computational study for bioactive phenolic compounds 
In silico appraisal presently happens to be a pronounced method of evaluation in various 
biological research these days. It has the benefit of low cost, fast execution, and the most 
constructive face of such study is to diminish the animal usage in various toxicity screening. 
PASS prediction assay (Lagunin et al., 2000) is highly studied these days which is based on 
primarily structure-activity relationships investigation of the training set that generally contains 
more than 200,000 compounds showing atleast not less than 3700 type of biological actions 
that interestingly allows to estimate if a phytochemical compound may have a particular effect 
(Dei et al., 2013). Lipinski’s Rule of Five (Lipinski, 2004) is another method that can be applied 
to all the phenolic compounds to evaluate their drug likeness and pharmacological properties. 
Such information is very helpful in accessing the phenolic compounds to be a potential drug 
lead that can act as natural therapeutics. Only the compounds satisfying the Lipinski’s criteria 
are further considered for further computational operations. Compounds that cleared the 
Lipinski’s barrier were prepared for docking studies by their energy minimization in Marvin 
Sketch. Receptor-ligand interaction study using Hex docking tool (Macindoe et al., 2010)  are 
also another mode of interaction study. Various amino acid of the target protein interaction 
with the lead compound are studied with respect to their bond length, bond angle. Hence, the 
reported phenolic compounds can thus be studied for good prospective of being used as 
medicine that targets various proteins for hepatic treatment. Reports of phosphorylated 
flavonoids i.e, iccartin is extensively studied for the potent target TGF-β where the score of 
molecular docking was reported 0.28 which was more than the marketed standard ursidiol 0.23 
(Wheng et al., 2016).  
Insilico studies have its implication in various pharmacological studies. From the initial 
protein, study to gene expression analysis related to any diseases can be carried out by the 
concept of pharmacogenomics. Phenolic compounds as hepatoprotective have been reported in 
the work of Kaveri et al., 2017, with insilico approach. The work was carried out on a group 
of newly synthesized acetylated phenolics. A good number of target proteins of hepatic 
anomaly have been reported when target fishing was performed (Liu et al., 2017); which not 
only predicted the probable important target but directed the study of those prospective target 
in understanding the mechanism of that diseaseThis mode thus supports the traditional uses for 
hepatic disorders and thus can suggest major bioactive phenolic compounds as contributors to 
produce ethnopharmacological effect.  
Future Prospects 
Natural products and specially plant phenolics have become a promising therapeutic alternative 
and prospective replacement of conventional marketed drug in practice due to their 
effectiveness, minimal side effects and protective properties. Further, their dietary nature and 
availability is an add on and makes it all the reason to decline those generally available drugs 
that also cause toxicity to cells. Remarkable phenolics like curcumin and resveratrol are 
pharmacologically tested chemoprotective agent against treatment of hepatic carcinoma. 
Though widely held natural products evaluated until now are generally non-toxic in nature, yet 
a few studies on toxicity by certain natural products are also highlighted these days. As a result, 
appropriate selection of the natural based drug is also obligatory. All the important phenolics 
with their derivatives though studied and well reported for its immense therapeutic usage a few 
of compounds are not yet fully analyzed, as there are not enough studies available regarding 
them. Components of such compounds in the dieta varies with temperature and cultivation 
process. Furthermore, variation in the physicochemical properties could result from different 
mode of production of such plants, including agricultural and environmental factor. Many 
pharmacological reports have demonstrated that phenols has a variety of therapeutic effects, 
including anti-cancer, anti-diabetic, anti-obesity, immunomodulatory, cardioprotective, 
hepatoprotective and neuroprotective effects through antioxidant and anti-inflammatory 
activities. However, additional studies are required to understand biological functions and 
compositions of many phenolic viz; iccartin, morin in more detail. Understanding biological 
function, composition, and therapeutic effects could help preventing adverse effects from long-
term administration of phenolic compounds, and developing health promoting properties. It is 
envisage from this presented review that plant based phenolics will not only reduce the risk of 
hepatopathy, but also will endow with an sure substitute towards various hepatotoxicity 
mediated diseases.  
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